ArticleCancer science2020

Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.

Hiroki Irie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.